

1 Regulation of Medical Devices in Zimbabwe: A qualitative 2 study with key stakeholders 3

4 Charles Chiku (Corresponding Author)¹, Talkmore Maruta², Fredrick Mbiba³, Justen Manasa⁴
5

6 ¹ Regulation and Prequalification Department, World Health Organization, Geneva, Switzerland

7 ² Programs, African Society for Laboratory Medicine, Lusaka, Zambia

8 ³ Biomedical Research and Training Institute, The Health Research Unit, Harare, Zimbabwe

9 ⁴ Department of Oncology, Faculty of Medicine and Health Sciences, University of Zimbabwe,
10 Harare, Zimbabwe
11

12 **Introduction:** Medical devices play a crucial role in promoting public health. However, there is a
13 disparity in the availability and readiness of medical device regulations in Resource-Limited Settings
14 (RLS) compared to the global average. We conducted a study to explore the medical device regulation
15 landscape and stakeholder perceptions in Zimbabwe.

16 **Methodology:** Between June and November 2022, we administered questionnaires to representatives
17 of the Medicines Control Authority of Zimbabwe (MCAZ), the Medical Laboratory and Clinical
18 Scientists Council of Zimbabwe (MLCScCZ), and the National Microbiology Reference Laboratory
19 (NMRL). We also conducted semi-structured interviews with 12 national-level critical stakeholders
20 from these institutions to understand the current status of medical device regulations and the
21 relationships between them. Additionally, we interviewed regulators from the South African Health
22 Products Regulatory Authority, Tanzania, and World Health Organisation to learn about best practices
23 in transitioning to medical device regulations. We used a thematic approach and an inductively
24 developed common coding framework to analyse emerging themes.

25 **Results:** Our findings indicate that the current legal framework needs to be revised to regulate medical
26 devices effectively, as it does not specify the institution(s) responsible for regulating them. While the
27 MCAZ regulates condoms and gloves, the MLCScCZ coordinates with the NMRL to register In Vitro
28 Diagnostic Medical Devices for priority diseases. Other medical devices are not regulated.
29 Furthermore, conformity assessments for product registration are not proportional to the risk
30 classification of medical devices, and post-market surveillance activities are ineffective. Stakeholders
31 recognise the need to collaborate and improve the regulation of medical devices.

32 **Conclusion:** Zimbabwe must improve its regulatory framework for medical devices to ensure that safe
33 medical devices of acceptable quality and performance are accessible. A solid legal foundation is
34 necessary for harmonisation and reliance practices to reduce the regulatory burden on economic
35 operators and ease the workload on regulators.

36 **Key Words:**

37 Regulation, Medical Devices, In Vitro Diagnostics, Safety, Safe, Quality, Performance, Reliance.

38

39 **Introduction**

40 The medical device regulations are a set of interlinked legislation and regulations that govern the
41 clinical investigation, production and distribution of medical devices, considering the medical device's
42 lifecycle based on its design, code of action and risk classification (1,2). A medical device is *"any*
43 *instrument, apparatus, machine, appliance, implant, reagent for in vitro use, software, material, or*
44 *related article used for a specific medical purpose"* (3). An in vitro device (IVD) is a medical device
45 used to examine specimens collected from humans for diagnostic information, monitoring, or
46 compatibility purposes (4). The general principle of medical devices regulation is to establish and
47 implement controls intended to safeguard the health and safety of patients, users and other persons by
48 ensuring that manufacturers of medical devices follow specified essential principles of safety and
49 performance during design, manufacture and marketing. Additionally, the risk controls must be
50 proportional to the risk classification of the medical device.

51

52 On the other hand, the regulatory controls must not impose an unnecessary regulatory burden on the
53 economic operators (manufacturers, importers, authorised representatives, distributors and
54 wholesalers) (5,6). Conformity assessment is based on the medical devices meeting all the applicable
55 Essential Principles (EP), which will be demonstrated and assessed according to procedures designated
56 by the Regulatory Authority and described in other Global Harmonisation Task Force (GHTF) and
57 International Medical Devices Regulators Forum (IMDRF) guidances (7). The GHTF, which later
58 changed to IMDRF, encourages and supports the global convergence of regulatory systems.

59

60 There are disparities in the availability of medical device regulatory services. According to the World
61 Health Organisation (WHO), about 40% of countries in the WHO Africa (Afro) region have no
62 regulations for medical devices, 32% have some regulations, and 28% have no data. In contrast, at the
63 global level, 58% of all WHO member states indicated they had medical device regulations (8). This
64 gap in medical device regulation between the Afro region and the global average may translate to lower-
65 quality medical devices and hinder access to quality-assured medical devices.

66

67 Zimbabwe is a low-income country in Southern Africa that may be affected by the disparity of medical
68 device regulation. In a study conducted by Hubner et al., it was concluded that Zimbabwe had a legal
69 framework for regulating medical devices, conformity assessment (evaluation conducted to approve
70 medical devices to be granted market access), import and export and post-market surveillance for
71 condoms and gloves only (9). A qualitative study to assess the regulation of HIV-Self Testing IVDs in
72 Malawi, Zambia and Zimbabwe was conducted by Dacombe et al. It was determined that the mandate
73 to regulate HIV-Self Testing IVDs overlapped between the Medical Laboratory and Clinical Scientists
74 Council of Zimbabwe and the Medicines Control Authority of Zimbabwe (MCAZ). Stakeholders
75 indicated they needed a better understanding of the process and requirements for HIVST regulation and
76 more clarity and coordination between organisational roles (10).

77

78

79 Additionally, the non-existing or weak regulatory system may have economic costs on the country due
80 to Substandard and Falsified (SF) medical devices. Underdeveloped regulatory systems are associated
81 with the regulatory burden for manufacturers to comply with unclear or different regulations when
82 seeking premarket approvals in other countries. Therefore, some manufacturers may be reluctant to

83 introduce their medical devices in countries with underdeveloped regulatory systems, which makes it
84 difficult for the population to access much-needed medical devices. On the other hand, the respective
85 National Regulatory Authorities (NRAs) must balance ensuring that the NRAs protect the public's
86 health and users through approved, safe, effective, acceptable quality and performance medical devices
87 while ensuring the efficient introduction of needed IVDs (6). There needs to be more data regarding
88 medical device regulation specific to Zimbabwe. Therefore, we conducted a qualitative study to
89 determine the current regulatory status of medical devices, including IVDs, to document the
90 perceptions and suggestions of key stakeholders to propose a roadmap to strengthen medical device
91 regulation.

92

93 **Methods**

94 Between June and November 2022, we conducted in-depth interviews to understand stakeholders'
95 relationships and perceptions of current and future medical device regulation (11). Specifically, we
96 sought to document stakeholders' current understanding and knowledge of medical device regulations
97 and to explore sensitive areas around how the development of regulation for medical devices can be
98 influenced by context and individual stakeholders. Data were collected using two approaches. First,
99 structured questionnaires containing closed and open-ended questions were administered to key
100 informants purposively selected due to their critical skills and knowledge of medical device regulations.
101 With this, we aimed to get an overview of the premarket and post-market controls in place to ensure
102 that only medical devices that were safe and effective were granted market authorisation and monitored
103 after approval. Questions were adopted from the study conducted by Rugera et al. that sought to
104 determine the regulation of medical devices in the East African Community partner states. Key areas
105 addressed were (i) the existence and role of regulatory authorities; (ii) policy and legal framework for

106 regulation; (iii) premarket control; (iv) marketing controls; (v) post-marketing controls(12). The tool
107 was composed of both open and closed-ended questions relating regulatory authority with the mandate
108 to regulate medical devices, if the legislation exists that empowers the regulatory authority, if there are
109 established definitions for medical devices and IVDs, the existence of established principles of safety
110 and performance, declaration of conformity by manufacturers, the basis for reliance and recognition,
111 compliance with ISO 13485 requirements for medical devices, labelling requirements, advertising of
112 medical devices, regulation of IVDs and post-market surveillance. The scale was Yes or No, with the
113 possibility of explaining in detail where applicable. One staff member completed questionnaires for the
114 three institutions (MCAZ, MLCScCZ and NMRL). Secondly, semi-structured interviews were
115 conducted with key informants from the MCAZ, MLCScCZ and NMRL. Selected regulators from
116 South Africa (SA), Tanzania and the WHO were selected to learn from them the best practices in their
117 transition to regulate medical devices effectively. Semi-structured interview questions focused on the
118 essential features of the WHO's Global Model Regulatory Framework for Medical Devices (13).

119 Secondly, for the semi-structured interviews, open-ended ones were structured to explore the essential
120 features of the medical devices regulatory system as recommended by the WHO Global Model
121 Regulatory Framework and the Global Benchmarking Tool (GBT). Questions were structured to
122 explore the existence and implementation of legal provisions and regulations for the following
123 regulatory functions:

- 124 • regulatory system,
- 125 • market authorisation,
- 126 • licensing establishment,
- 127 • regulatory inspection (manufacturing site inspection),

- 128 • laboratory testing, and
- 129 • post-market surveillance.

130 To ensure the validity of the questions, the questions were adapted from the GBT. The GBT is the
131 globally accepted standard for benchmarking regulatory authorities (14,15).

132

133 **Setting and Participants**

134 The questionnaires were completed by representatives of the Medicines Control Authority of
135 Zimbabwe (MCAZ), the Medical Laboratory and Clinical Scientists Council of Zimbabwe
136 (MLCScCZ), and the National Microbiology Reference Laboratory (NMRL). The MCAZ is the NRA
137 with the legal mandate to regulate medicines and allied substances. The MCAZ also regulates condoms
138 and gloves as medical devices. The MLCScCZ is a health professional regulatory body that regulates
139 the practices of medical laboratory professionals and some operations of medical laboratories. The
140 MLCScCZ coordinates performance evaluations to grant IVDs access to national tenders related to
141 HIV, TB, Malaria and STIs IVDs. The NMRL is the reference laboratory that conducts performance
142 evaluations for market approvals that the MLCScCZ grants. Representatives regulating medical
143 devices were purposively selected to complete the questionnaire to provide rich, relevant and diverse
144 data pertinent to the research question (see file S1).

145 After developing a list of potential participants with input from key informants, regulatory documents
146 and local knowledge, we used purposive sampling to identify eight participants from the MCAZ,
147 MLCScCA, and NMRL to interview. We further supplemented this list by snowball sampling, reaching
148 12 interviewed participants—this brought the total number of participants from the MCAZ to four.
149 Although the MCAZ has several units, the Medical Devices and Microbiology unit was selected as the

150 interview focus because staff members in that unit are involved in market authorisation, manufacturing
151 site inspections, laboratory performance evaluations and licensing activities. Staff members from the
152 MLCScCZ ($N = 4$) were interviewed to gain an in-depth understanding of the IVD evaluation process.
153 Staff members responsible for coordinating and performing laboratory testing of IVDs were
154 interviewed at the NMRL ($N=4$)—table 1. The interviews were conducted face-to-face, and some were
155 conducted remotely using Zoom and Microsoft Teams applications. All interviews were audio recorded
156 after informed consent was obtained from participants. See Table 1 for participants' characteristics,
157 participants that completed the questionnaires and those that were interviewed. Regulators South
158 Africa's regulatory, South African Health Products Regulatory Authority (SAHPRA) and Tanzania,
159 Tanzania Medicines and Medical Devices Authority (TMDA) were also interviewed to learn best
160 practices and lessons learnt when the two countries established and implemented medical device
161 regulations. The two countries were specifically chosen because of their tremendous medical device
162 advancements in the Southern and Eastern African regions. Lastly, a WHO Regulatory Systems
163 Strengthening representative was interviewed to understand the coverage of the WHO Global Model
164 Regulatory Framework for Medical Devices in the Afro region and how it can be used to establish and
165 strengthen medical device regulations. The idea was to use come up with a road map that is harmonised
166 with other regional and international medical device regulations.

167
168
169
170
171
172
173
174
175

176

177 **Table 1: Characteristics of Interview Participants interviewed in Zimbabwe between June to**
 178 **November 2022**

Participant	Institution	Organisation role	Structured questionnaire administered (Y/N)	Interview (Y/N)
KI01	MCAZ	Medical Devices Senior Analyst	Y	Y
KI02	NMRL	Acting Chief Medical Laboratory Scientist	Y	Y
KI03	MLCScCZ	Registrar	N	Y
KI04	MLCScCZ	Former Chairman	Y	Y
KI05	NMRL	Medical Laboratory Scientist (MLSc)	N	Y
KI06	MCAZ	Medical Devices Senior Analyst	N	Y
KI07	MLCScCZ	Council Committee member	N	Y
KI08	NMRL	MLSc	N	Y
KI09	NMRL	MLSc	N	Y
KI10	MCAZ	Medical Devices Analyst	N	Y
KI11	MCAZ	Regulatory Officer	N	Y
KI12	MLCScCZ	Council Committee Member	N	Y

179 *Note.* MCAZ = Medicines Control Authority of Zimbabwe; MLCScCZ = Medical Laboratory and Clinical
 180 Scientists Council of Zimbabwe; NMRL = National Microbiology Reference Laboratory.

181

182 **Data Analysis**

183 The Consolidated criteria for reporting qualitative research (COREQ) were used to ensure that all
 184 relevant information was included when preparing this manuscript. The criteria included the research
 185 team, study methods, context of the study, findings, analysis and interpretations (14). The researchers
 186 introduced themselves to the participants to avoid bias by stating their identities, credentials,
 187 occupation, gender, experience and training. The researchers did not have a relationship with any

188 participants as an additional measure to mitigate bias. The study method was based on a content
189 analysis theoretical framework to determine specific words, themes, or concepts within the qualitative
190 data. Data were analysed using NVivo qualitative software version 12. Interview records were
191 transcribed verbatim. Data was coded deductively using a coding frame and inductively by adding
192 codes emerging from the data. CC and FB independently coded a subset of four transcripts each and
193 then met to determine consensus and minimise intercoder variability for quality control purposes. The
194 themes that emerged from the data analysis were acts, regulations and guidelines. For each theme,
195 codes were developed for subthemes. The usefulness of these codes was tested by using this coding
196 framework to code the first four transcripts in NVivo. Subsequently, the codes were discussed with and
197 validated by a second researcher. Participants were assigned a code to maintain their anonymity, with
198 codes reflecting their organisation (e.g., MCAZ KII7 was assigned to a participant from the MCAZ).

199 **Ethical Considerations**

200 Ethical approval for this study was obtained from the Medical Research Council of Zimbabwe
201 (MRCZ/A/2900). Participation was voluntary. Participants were able to stop the interview at any time
202 without explanation. Written informed consent was obtained from each study participant before each
203 interview. The interview content and the interviewee's identity were kept anonymous.

204

205 **3. Results**

206 **3.1 Section A: Questionnaire Findings**

207 Based on questionnaire responses, it was found that at the time of this study, the MCAZ, MLCSscZ
208 and NMRL did not have the explicit legal mandate to regulate medical devices, including IVDs. The
209 MCAZ regulated condoms and gloves. The MLCSscZ, in collaboration with the NMRL, were

210 conducting laboratory evaluations for market authorisation of IVDs for case management of HIV,
211 Malaria, Tuberculosis, Syphilis, and Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-
212 2). Medical devices were not regulated, including IVDs for human and veterinary use, IVDs used in
213 the public and private sectors, and IVDs for blood products. Participants from the MCAZ and
214 MLCSscZ indicated that the regulations are still in the draft stage and need to be implemented.
215 Regulatory functions focusing on premarket (assessment to grant market approval), marketing controls
216 and post-market surveillance for medical devices (excluding condoms and gloves) and IVDs were not
217 implemented.

218

219 **3.2: Results from Semi-structured Interviews**

220 Stakeholders from Zimbabwe were interviewed to explore their perception of the current and future
221 status of medical device regulation. Results from the interviews are presented in two sections. The first
222 section includes interviews with Zimbabwe stakeholders, and the second includes interviews with
223 regulators outside of Zimbabwe.

224

225 **3.2.1. Results from Interviews with Stakeholders from Zimbabwe**

226 Semi-structured interviews were conducted with 15 participants, 12 of whom were critical stakeholders
227 in medical device regulation in Zimbabwe. The themes identified from the interviews were categorised
228 under critical components of a regulatory system. Transcripts were reviewed first, and data were
229 organised by categories that had emerged during the review, i.e., connected verbatim quotes were
230 categorised. We then reviewed and interpreted the quotes within each category. This enabled us to
231 identify six main themes across our interview data. The six themes included: limited legal framework;
232 limited regulatory capacity; conformity assessment not proportionate to risk classification, lack of

233 post-market surveillance; the need to improve the medical devices regulatory system; and collaboration
234 of regulatory authorities. See Table 2 for themes and quotes from participants capturing the themes.

235

236 **3.2.1.1 Theme 1: Limited legal framework**

237 The regulation of medical devices in Zimbabwe is based on something other than an effective and
238 efficient legal and policy foundation. The MCAZ assumed the mandate to regulate medical devices,
239 including IVDs using the Medicines and Allied Substance Control Act (MASCA). On the other hand,
240 the MLCScCZ assumed to mandate to regulate IVD medical devices based on the Health Professions
241 Act. The MASCA was initially gazetted following the medicines framework and missed some critical
242 medical device regulation aspects. For example, the law must clearly state the scope of regulated
243 medical products and identify the entities subject to regulation.

244

245 **Table 2: Main themes emerging from the interviews of medical device regulatory stakeholders in**
246 **Zimbabwe conducted between June to November 2022**

Theme	Source	Supporting quote
Limited legal framework	MCAZ KII7	“We do not specifically have legal provisions and regulations for medical devices. However, for condoms and gloves that are currently being regulated, we leverage the medicines framework because it has been in place for a while and has matured.”
	MCAZ KII6	“The current MCAZ does not have a law for recognition and reliance. This is because it was

written before that drive for recognition, reliance and work sharing existed. So, uh, currently, there is work sharing. There is reliance on licensing and evaluations and a bit on pharmacovigilance.”

MCAZ “We don’t have legal provisions or regulations

KII10 per se, but we have a policy on reliance and recognition published in 2020 or 2021. It states the institutions we rely on for IVD and non-IVD medical devices.”

Limited regulatory capacity

MCAZ KII5

“From the onset of HIV, the then minister of health realised the challenges we would face when we have a pandemic. So, we then directed the medical laboratory council to evaluate what kits were used. They used to call it an evaluation of test kits and devices for HIV, and then it extended to malaria and TB. But the onset of it started during the time of HIV/AIDS when the government needed to have one system of testing HIV and AIDS so that they use the same parameters and guidelines to ascertain the impact of HIV and AIDS without using a multiplex of kits.”

	MCAZ KII1	“We test for gloves though there are low risk because of HIV, and condoms are tested because we have been hit so badly.”
	NMRL KII8	“Well, I don’t think IVDs are effectively regulated. The regulation seems to be reactive to the needs of the national disease programmes such as HIV/AIDS, TB and Malaria. There is no explicit IVD policy on how these products must be regulated. Other IVDs outside the stated disease programmes are not subjected to regulation, including those used in the private sector. So, my honest opinion is that IVDs are not effectively regulated.”
Consistent conformity assessment not proportional to risk classification	MCAZ KII11	“Yes, for gloves, the conformity assessment is not proportional to the risk class of the device since some types of gloves are in Class A. Draft regulations include risk classification rules, and we are planning to assess medical devices based on the risk class. That is, high-risk products will be subjected to a more stringent conformity assessment to be granted market access.”

	MCAZ KII1	“Medical Devices with lower risk will not be tested, that is Classes A and B and just require notification, then classes C might require ISO certification and D must be tested including the manufacturing site inspection.”
	MCAZ KII7	“At the moment we do not have medical device classification rules published. However, we have them included in the draft Import and Export of Medical Devices) Regulations, 2017.”
Lack of post-market surveillance	MCAZ KII1	“Currently, we have not been doing it. We have really not been doing much from our end. That has been our weakness. The only thing we have been doing is going around the country to check for unregistered medical devices. Our regulations are not so explicit on post-market surveillance.”
	MLCScCZ KII4	“There are no regulations for economic operators, including manufacturers, authorised representatives, distributors or importers, to mandate them to conduct post-market surveillance-related activities.”

The need to improve the medical devices regulatory system

NMRL KII8 “Well, the need for regulation must be balanced, but we cannot do all the regulatory functions. There is a need to have training and technical support, including infrastructure and equipment to conduct the regulatory functions, human resources that are trained and competent to conduct the work, and mechanisms to ensure transparency and accountability.”

MCAZ KII7 “The MCAZ is working towards starting with essential controls for medical devices. This is why we started drafting Import and Export Control of Medical Devices regulations so that we can have an appreciation of the medical devices coming into or leaving the country. This will help us know the market size and prioritise the regulation of devices that are of public health importance and high risk in line with the IMDRF guidance.”

Collaboration of regulatory authorities

MCAZ KII7 “We’re also working with the Medical Laboratory and Scientists Council to have an expert committee that can advise of regulatory functions of IVDs within MCAZ since the

council is conducting some market
authorisation assessments for IVDs together
with NMRL.”

247 *Note.* MCAZ = Medicines Control Authority of Zimbabwe; MLCSscCZ = Medical Laboratory and Clinical
248 Scientists Council of Zimbabwe; NMRL = National Microbiology Reference Laboratory.

249

250 Additionally, there is no general requirement that only medical devices that are safe, of acceptable
251 quality, and performance must be authorised to access the Zimbabwean market. However, during the
252 interviews, MCAZ respondents noted that the MCAZ regulated condoms and gloves as part of medical
253 devices, stating: “*We do not specifically have legal provisions and regulations for medical devices.*
254 *However, for condoms and gloves that are currently being regulated, we leverage the medicines*
255 *framework because it has been in place for a while and has matured*” (MCAZ KII7). The MLCSscCZ
256 was conducting registration for IVDs specific for priority diseases for the national tendering process,
257 “*But not to say they have the powers to do it, the council would report from the of the approved products*
258 *for tendering process with data produced from the evaluation by the experts’ committee*” (MLCSscCZ
259 KII4).

260

261 The MCAZ had drafted regulations for the Import and Export of Medical Devices and In Vitro
262 Diagnostic Medical Devices, but these were yet to be approved during the interviews. The MCAZ had
263 plans to amend the MASCA to include all health products that require regulation: “*Exactly. Currently,*
264 *there is a bill that has been drafted, so you will see MCAZ changing its name to a name that*
265 *encompasses other products. Currently, the name implies control of medicines only, but there are*
266 *discussions with the Ministry of Health for the name to encompass all medical products.*” (MCAZ
267 KII1). It was unclear if the NMRL had a legal mandate to conduct laboratory testing for regulatory

268 purposes: “Ummm, it is unclear as far as legislation is concerned. However, it has been known within
269 NMRL and the Ministry of Health that the NMRL conducts performance evaluations for IVDs for the
270 Medical Laboratory and Clinical Scientists Council of Zimbabwe to register products procured
271 through national tendering processes”(NMRL KII8). Furthermore, the legislation that mandates
272 NMRL to perform laboratory testing functions for regulatory purposes was unclear. One interviewee
273 responded to the question of the existence of the Act of Parliament that established the NMRL if it
274 included conducting regulatory functions for IVDs by saying, “ I have heard there is an Act Parliament,
275 but we have failed to locate it. So, it is unclear whether the act exists and what mandates are given to
276 NMRL according to the act.” (NMRL KII8).

277 Therefore, the legislation in Zimbabwe needs to be more explicit on the institutions involved in
278 medical device regulation and that medical devices, including IVDs, that meet specific safety, quality,
279 and performance requirements must be authorised to access the market.

280

281 **3.2.1.2 Theme 2: Limited regulatory capacity**

282

283 The MCAZ was regulating condoms and gloves only at the time of the interview. Other medical devices
284 were not regulated. The capacity to regulate IVD medical devices in the MCAZ seems limited. They
285 were engaging the MLCSscZ to have an experts committee to assist with the regulatory functions of
286 IVDs within the MCAZ in the future: “The technical committee approves, and then they are shared
287 with external stakeholders, at some stage, they should be a stakeholder consultation that includes
288 MLCSscZ, HPA, Ministry” (MCAZ KIII). The MLCSscZ also showed its challenges in regulating
289 IVDs and was keen to work with the MCAZ since it has some expertise in other health products such
290 as medicines, condoms and gloves: “So we're going to be looking at a manufacturing site, which
291 manufacturer bringing in IVDs. I think we'll do it like what MCAZ does for drugs cause they do a

292 *thorough job cause I worked with those guys. They do go even to where those things are being*
293 *manufactured to see what they're saying is what they supposed to do” (MLCScCZ KII3).* During the
294 interviews, respondents noted that the MLCScCZ used only performance verification results from the
295 NMRL to make registration decisions for IVD registration. The NMRL had challenges related to staff
296 not being trained on the regulatory functions of the laboratory, non-availability of Clinical Laboratory
297 and Standards Institute guidelines and testing panels (reference samples), and testing protocols were
298 not standardised to meet the CLSI guidelines: *“Yes, because we do not have well-characterised*
299 *specimen panels, and we have to rely on results from other institutions, such as condemned blood from*
300 *the National Blood Services.” (NMRL KII9).*

301 Overall, the institutions currently regulating medical devices have limited capacity in terms of
302 resources, expertise and processes to regulate medical devices, including IVDs, effectively.

303

304 **3.2.3. Theme 3: Conformity Assessment not proportional to risk classification**

305

306 The MCAZ conducted conformity assessments for condoms and gloves. However, there are no criteria
307 for the classification of medical devices using established classification rules to guide the level of
308 scrutiny the product must be subjected to. *“At the moment we do not have medical device classification*
309 *rules published. However, we have them included in the draft Import and Export of Medical Devices*
310 *Regulations, 2017” (MCAZ KII7).* However, some gloves are Class A and are regulated with the same
311 stringency as Class C devices: *“Yes, for gloves, the conformity assessment is not proportional to the*
312 *risk class of the device since some types of gloves are in Class A. Draft regulations include risk*
313 *classification rules, and we are planning to assess medical devices based on the risk class. That is,*
314 *high-risk products will be subjected to a more stringent conformity assessment to be granted market*
315 *access.” (MCAZ KII11).*

316 No risk-based approach is currently in place to classify medical devices that work as a precursor to
317 deciding on the level of scrutiny the medical devices will be subjected to during conformity
318 assessments.

319

320 **3.2.4. Theme 4: Lack of post-market surveillance**

321 The MCAZ was not conducting formal PMS for gloves and condoms besides routine inspections
322 following the pharmacovigilance framework of medicines. *“Currently, we have not been doing it. We
323 have really not been doing much from our end. That has been our weakness. The only thing we have
324 been doing is going around the country to check for unregistered medical devices. Our regulations are
325 not so explicit on post-market surveillance” (MCAZ KII1).* The MLCScZ gets reports on IVDs,
326 but the process is poorly documented. There are no documented obligations for economic operators
327 (manufacturers, importers, authorised representatives, distributors and wholesalers) to conduct PMS
328 activities: *“Yes, from the regulatory side and any economic operator looking at the manufacturers,
329 authorised representatives, distributors or in importers, such things are not clearly defined on how
330 the process should go about” (MLCScZ KII03).*

331 PMS regulations and procedures are not documented. Therefore, there is no assurance that the products
332 on the market and in use are still safe, of acceptable quality and performance.

333

334 **3.2.5. Theme 5: The need to improve the medical devices regulatory system**

335 There was a consensus from the participants that medical device regulation needed to be improved.
336 Regulation of medical devices has been suboptimal: *“Well, I don’t think IVDs are effectively regulated.
337 The regulation seems to be reactive to the needs of the national disease programmes such as HIV/AIDS,
338 TB and Malaria. There is no explicit IVD policy on how these products must be regulated. Other IVDs
339 outside the stated disease programmes are not subjected to regulation, including those used in the*

340 *private sector. So, my honest opinion is that IVDs are not effectively regulated*” (NMRL KII8). The
341 MCAZ has drafted regulations and is amending the MASCA: *“The MCAZ is working towards starting*
342 *with essential controls for medical devices. This is why we started drafting Import and Export Control*
343 *of Medical Devices regulations so that we can have an appreciation of the medical devices coming into*
344 *or leaving the country. This will help us know the market size and prioritise the regulation of devices*
345 *that are of public health importance and high risk in line with the IMDRF guidance*” (MCAZ KII7).
346 *My desire is to see the regulation of IVDs harmonised with international best practices. For example,*
347 *we can use best practices such as those applied for WHO Prequalification and other mature regulatory*
348 *authorities* (MLCScCZ KII11). There is a general willingness from stakeholders to improve the
349 regulation of medical devices, and suggestions have been given on this can be done.

350

351 **3.2.6. Collaboration of regulatory authorities**

352 Despite unclear legislation on the institutions with the mandate to regulate medical devices, efforts
353 have been made to allow for collaboration between the MCAZ and MLCScCZ. The two institutions
354 are finding each other, recognising the expertise and role each institution can contribute to effectively
355 regulating medical devices. *“We’re also working with the Medical Laboratory and Scientists Council*
356 *to have an expert committee that can advise on regulatory functions of IVDs within MCAZ since the*
357 *council is conducting some market authorisation assessments for IVDs together with NMRL*” (MCAZ
358 KII7). The role the NMRL plays in conducting laboratory testing for regulatory purposes is also
359 recognised by the MCAZ: *“... the NMRL will continue doing what they were doing. But they'll work*
360 *more like, um, assessment bodies where they will test on behalf of the regulator. Then they give The*
361 *results to the regulator so that the regulator only does the evaluation process, but not testing of the, of*
362 *the kits.*” (MCAZ KII6). Another respondent had this to say, *“ This requires a pragmatic approach,*
363 *that includes building the capacity of regulators, infrastructure, a collaboration between institutions*

364 *based on their expertise, and leadership. We need now to think of this as a system, not as a way of*
365 *protecting specific professions but as putting the safety of the patients at the centre (MLCScZ*
366 *KII11)”. The responses clearly show the need to collaborate and the willingness of key stakeholders to*
367 *come together to establish and strengthen medical device regulations.*

368

369

370

371 **3.2.2 Results from Interviews with Regulators Outside of Zimbabwe**

372 One regulator from SAHPRA and the other from TMDA were interviewed to understand the journey
373 SAHPRA and TMDA went through when they transitioned from regulating medicines to including
374 medical devices in the scope of regulated medical products. Lessons learnt and best practices were
375 documented to aid in drafting the roadmap for developing medical device regulations in Zimbabwe and
376 for harmonisation purposes. The WHO representative was interviewed to understand the
377 implementation and coverage of the Global Model Regulatory Framework for Medical Devices and
378 how countries can use it to strengthen medical device regulation. Tables 3 and 4 show the
379 characteristics of the interviewees and the themes that emerged from the interviews.

380

381

382

383

384 **Table 3: Characteristics of Key Informants that Participated in Interviews from outside of**
385 **Zimbabwe between June and November 2022**

Key Informant	Institution	Role in the organisation
WHO KII13	WHO	Technical Officer
SAHPRA KII14	SAHPRA	Senior Manager, Medical Devices and Radiation Control
TMDA KII15	TMDA	Manager, Medical Devices and Diagnostics Control

386 **Note** SAHPRA= South African Health Products Regulatory Authority; TMDA=Tanzania Medicines and
387 Medical Devices Authority

388

389 **Table 4: Main themes emerging from the June to November 2022 interviews on Key Informants**
390 **from outside Zimbabwe.**

391

Theme	Source	Supporting Quote
Use of WHO GMRFMD	WHO KII13	“And so I do not have data, but I understand this is one of the top, I can say reference documents for regulators when they're introducing, uh, the framework for devices. And the other aspect that are trying to accommodate now in the revised version is to make sure that the model also addresses advanced regulatory authorities.”

	WHO KII13	“We realised that the indicators for the GBT plus medical devices would need to align as much as possible with the WHO global model regulatory framework.”
Use of GBT	SAHPRA KII14	“So the roadmap indicated that they’re following the WHO Global Benchmarking (GBT) process for implementing the medical device regulations in the country.”
Streamline legislation	TMDA KII15	“We came up with a draft of regulations for 2015 control of medical devices, including in vitro diagnostics....Regulations didn't go to the parliament. So the minister only, um, requested for minor amendments of the law to include IVDs. So IVDs were approved through the parliamentary, um, request to include IVD.”
	SAHPRA KII14	“So we have an ACT called Act 101 of 1965, which is the Medicines and Related Substances Act. So before 2017, the ACT was not explicit in regulating medical devices and IVDs. So, the

MCC didn't have the leg to stand on if I could put it on to regulate the medical devices. So if you look at it, there are a lot of changes in the legal framework. So that was one area that the MCC focused on.

So there was an update to the ACT that was done around 2017.”

International and regional harmonisation SAHPRA KII14

“And I think another point that you're raising, and I think it's something that you need to indicate, is Zimbabwe must have a look at joining various forums that will assist us towards harmonisation. Like the African Medical Device Forum and the Global Harmonisation Working Party (GHWP), because those platforms have other national regulatory authorities, as you indicated, I'm part of the AMDF.”

WHO KII13

“So we made sure that we had a, a lot of references, we had a lot of information from other mature jurisdictions such as, such as the USFDA, TGA, Japan, all these other big, uh, national regulatory authorities to say what is happening in

		other countries that have made, uh, uh, tremendous, uh, progress in this, in this space.”
Stakeholder engagement and advocacy	WHO KII13	“So we started, uh, advocacy or awareness, if I can call it that way, at the ministry at the top, a leader of the ministry, so the minister and other people in the ministry.”
	TMDA KII15	“So this, there's nothing you can do rather than stakeholder engagements and stakeholder meetings at all levels. Relate to them what benefits, what advantages are there when the products are being admitted in this way, and what does the international community think, what's their thinking of the international community about the regulation of these products.”
The transition period to implement new regulations	SAHPRA KII14	“So in that process, there was a transition period of about two years to make applications and afterwards to set themselves up. Then afterwards, in 2019, no companies were longer allowed to operate without registration.”
	TMDA KI15	“When we started, there were already IVDs, especially for malaria and HIV, already registered

by public health, private health laboratories board,
so what we did was first to grandfather those
registrations as the basis for importation, then we
give them a rest period for them to now submit the
technical dossiers to TMDA for evaluation and for
registration.”

392 **Note:** WHO GMRFMD=World Health Organisation Global Model Regulatory Framework for Medical Devices;
393 GBT= Global Benchmarking Tool, SAHPRA= South African Health Products Regulatory Authority;
394 TMDA=Tanzania Medicines and Medical Devices Authority

395

396 **3.2.2.1 Use of WHO GMRFMD**

397 The WHO GMRFMD was recognised as a reference to establish and improve medical device
398 regulations. In a survey that the WHO conducted in the Afro region, about 60% of the countries had
399 awareness and used the framework: “ *So we are looking at maybe 58 % understanding of the model.*
400 *And also, uh, using it to, as a guidance, uh, as a reference document, uh, for the regulation of medical*
401 *devices and IVDs. It's unfortunate that we didn't conduct a global survey.*” (WHO KII13). The WHO
402 GMRFMD is an acceptable framework that countries can use to establish and strengthen medical device
403 regulations.

404 **3.2.2.2 Use of GBT**

405 South Africa used the GBT to map its way to improving the medical devices regulatory system. The
406 GBT has indicators that are used to benchmark the regulatory system and the development of an
407 institutional development plan that can be implemented and monitored: “ *So the roadmap indicated*
408 *that they're following the WHO Global Benchmarking (GBT) process for implementing the medical*

409 *device regulations in the country (SAHPRA KII13)*". Revision of the GBT to include medical devices
410 has presented an opportunity for the WHO GMRFMD to be revised to cover both basic and advanced
411 controls for medical devices. The WHO representative said, "*And, so the discussion in the GBT*
412 *indicators triggered revision. And this is why there is an ongoing discussion to update and revise the*
413 *model (WHO KII13)*". The WHO GMRFMD needs to be utilised together with the GBT as the two
414 work together for institutions to develop and strengthen their regulatory systems.

415 **3.2.2.3 Streamline legislation**

416 NRAs from South Africa and Tanzania had to amend their legal framework to ensure medical device
417 regulation was above board. In the South African case, the law was amended to allow the name change
418 of the NRA and the law to regulate medical devices. "*So while it was still MCC before 2017, some*
419 *regulations were published, and then the industry was pushing back on them and an update to the*
420 *legislative framework, which is the ACT. So we have an ACT called Act 101 of 1965, which is the*
421 *Medicines and Related Substances Act. So before 2017, the ACT was not explicit in regulating medical*
422 *devices and IVDs. So, the MCC didn't have the leg to stand on if I could put it on to regulate the medical*
423 *devices.*" (SAHPRA KIII13). The Tanzanian NRA representative had this to say about the change in the
424 legal framework, "*So the minister only, um, requested for minor amendments of the law to include*
425 *IVDs. So IVDs were approved, uh, through the parliamentary, um, request to include IVD. So that was*
426 *included, amendment of the definition, the inclusion of the risk classes of devices. And then, uh, it gave*
427 *the minister also power to make other regulations. So we used that clause to develop specific*
428 *regulations for medical devices. And so, uh, the minister signed the regulations in 2015(TMDA*
429 *KIII5).*"The legislation is the foundation for regulation to be established and enforceable.

430

431 **3.2.2.4 International and regional harmonisation**

432 Tanzania conducted an assessment to devise ways of harmonising the medical device regulations. The
433 assessment was conducted by looking at regulations from mature regulatory authorities such as the
434 United States of America Food and Drug Administration (USFDA), the Australian Therapeutic Goods
435 Administration (TGA), and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). “ So
436 *we made sure that we had a, a lot of references, we had a lot of information from other mature*
437 *jurisdictions such as, such as the USFDA, TGA, Japan, all these other big, uh, national regulatory*
438 *authorities to say what is happening in other countries that have made, uh, uh, tremendous, uh,*
439 *progress in this, in this space for harmonisation purposes (WHO KII15).” Tanzania’s regulatory*
440 *authority framed its regulations following the IMDRF framework to ensure harmonisation. “ Of course,*
441 *it was very much mirrored from medicine’s regulatory framework, as well as at that time, the IMDRF*
442 *mode of regulation to ensure harmonisation.” (WHO KII15). SAHPRA representative encouraged*
443 *Zimbabwe to join harmonisation initiatives to learn best practices from other regulatory authorities. “*
444 *And I think another point that you’re raising, and I think it’s something that you need to indicate, is*
445 *Zimbabwe must have a look at joining various forums that will assist us towards harmonisation. Like*
446 *the African Medical Device Forum and the Global Harmonisation Working Party (GHWP), because*
447 *those platforms have other national regulatory authorities, as you indicated based, I mean, I’m part of*
448 *the AMDF. So there is already another regulator in that platform (SAHPRA KII13).” South Africa*
449 *and Tanzania harmonised their regulations with other stringent regulatory authorities, which is*
450 *commendable.*

451 **3.2.2.5 Stakeholder Engagement and Advocacy**

452 Stakeholder engagement and advocacy were conducted during the medical device regulations
453 formulation. The engagement was done at different levels, from technical departments to policymakers

454 in the Tanzanian context. “*So if the minister is on our side, if the policymakers, if the, uh, permanent*
455 *secretary of the Minister of Health and the directors at the Minister of Health understand where we*
456 *are going wrong, then definitely we would have supposed to say, you know, guys, we need to correct*
457 *this. So we started, uh, advocacy or awareness, if I can call it that way, at the ministry at the top, a*
458 *leader of the ministry, so the minister and other people in the ministry.*” (WHO KII13). In the South
459 African context, the mandates were clearly defined based on legislation, so engagement with other
460 stakeholders in regulating medical devices was not complicated. “*Cause that’s not their mandate. So*
461 *exactly. Now, for example, our act has radioactive medical devices. We also have national regulatory*
462 *authority. But they cannot take the health product all these years; they were just sitting in the Ministry*
463 *of Health. They couldn’t take it. They can look after the isotopes and this big Eskom stuff that produces*
464 *radiation, but they couldn’t come across that boundary to come and do medical devices and IVDs*
465 *because the legal framework prohibits them to do so (SAHPRA KII14)”. It is clear from the interviews*
466 *that stakeholder engagement and advocacy are essential so that parties involved in medical device*
467 *regulations know their mandates and that the leadership is involved in the process.*

468 **3.2.2.6 Transition period to implement new regulations**

469 When new regulations were promulgated in South Africa and Tanzania, there was a transition period
470 for economic operators to comply with the new regulations. This was done so that there was no
471 disruption in access to medical devices. “*So in that process, there was a transition period of about two*
472 *years to make applications and afterwards to set themselves up. Then afterwards, in 2019, no*
473 *companies were longer allowed to operate without registration, so what we did is that company will*
474 *send applications cause the applications and the guidelines were drafted, companies will send*
475 *applications, and then SAHPRA would give them a letter of acknowledgement so that there is no*
476 *disruption in the business because there were lots of applications that came about 600, 700 in a year.*”

477 (SAHPRA KII14). Tanzania allowed IVDs registered by the Private Health Laboratory Board (PHLB)
478 to access the market and gave a transition period for the manufacturers to formalise the registration of
479 their IVDs. “ *So we had to rely on that status, at least for the first year, before we can allow them to*
480 *apply for full registration. And also, even when we were grandfathered in there when we were now*
481 *registering them, we used to recognise the performance that was being carried out by the PHLB*
482 *because what PHLB, so their mode of regulation was only on performance, while ours is around all*
483 *the areas of regulation, including site performance. (TMDA KII15).” The introduction of regulations*
484 *mustn't work as a barrier for the population to access medical devices when new regulations are*
485 *introduced.*

486

487 **Discussion**

488 Medical device regulation ensures that medical devices approved for use meet the specified safety,
489 quality and performance requirements to protect public health (7). Regulation must be based on a solid
490 legal framework to be enforceable. The legislation details the mandate of the national regulatory
491 authority, regulatory system, scope of regulated medical products, definitions of regulated medical
492 devices, and regulatory functions of the NRA or other institutions. Regulations interpret the legislation,
493 law or act and allow the NRA to establish and implement principles to ensure the safety and
494 performance of medical devices and evaluate if the medical devices used in public and private sectors
495 are regulated (2). One of the significant findings of this study was that Zimbabwe does not have a
496 formal medical devices regulatory system. Medical devices other than condoms and gloves, donated
497 medical devices, IVD medical devices for human and veterinary and human blood products are not
498 regulated. Hubner et al. had a similar finding when they investigated the landscape of medical device

499 regulatory systems in East, Central and Southern Africa. However, Hubner et al. concluded that
500 Zimbabwe had a legal framework for medical devices (9). This contradicts our finding, as the
501 participants stated that the law is not yet amended to regulate medical devices. The differences may be
502 due to methodological differences, as Hubner et al. used a literature review. Considering the shortage
503 of literature in the Zimbabwean context, the granularity of information is limited. The participant who
504 completed the questionnaire from MCAZ responded to question number two on the questionnaire,
505 *"Does your institution has a legal mandate to regulate medical devices, including IVDs?"* as *"Not yet.*
506 *The regulations are still in draft stage and not yet approved/gazetted for implementation"*(MCAZ
507 KII1).

508 Additionally, the legal framework (MASCA) was made specifically for medicines and allied substances
509 but did not have a formal definition of a medical device. The WHO recommends it in the GMRFMD
510 for the legal framework to clearly define medical devices and the scope of these devices that must be
511 regulated to ensure that only medical devices that meet conformity assessment are granted market
512 authorisation and approved for use (13). The difference between Hubner et al.'s and our study on the
513 presence of the legal framework may be due to the way questions were structured to collect this
514 information. In our study, semi-structured interviews complemented questionnaires to triangulate the
515 findings from questionnaires and semi-structured interviews. Additionally, we utilised a case study
516 strategy to probe deeply and analyse the myriad phenomena that constitute the complexities of the
517 medical devices regulatory system. Hubner et al. used a literature review methodology. Although there
518 was a contrast, some similarities were observed in these two studies. For instance, both researchers
519 identified the following deficiencies: non-existence of the definition of medical device, risk-based
520 classification of medical devices, and essential principles. Essential principles, conformity assessment,
521 and registration components were found to be in place for gloves and condoms for both studies (9).

522

523 The MCAZ had drafted regulations for the Import and Export and Export of Medical Devices and In
524 Vitro Diagnostic Medical devices, but they were yet to be approved. It is unclear when these regulations
525 will be approved: “ *As for the timelines, we have played our part. We have drafted, and the approval*
526 *is with the ministry; that’s where delays are. Our team has been pursuing, still pursuing. The ones that*
527 *I am certain are going to be gazetted but outside of the scope of the study are for the regulation of*
528 *blood and blood products. The ones for medical devices and IVDs I don’t know..” (MCAZ KII1). “In*
529 *terms of, uh, the timeline, uh, in terms of MCAZ as a timeline, if we, if we had entirely on us, probably*
530 *would’ve been like December. But now there’s so many things at play” (MCAZ KII6). The delays in*
531 approving the draft regulations may be due to a lack of autonomy by the MCAZ to make approval
532 decisions. On the other hand, these draft regulations are not supported by a sound basis in law that must
533 include definitions of the products within its scope and identify the entities subject to regulation (13).

534

535 This finding implies that medical devices are not effectively regulated except for condoms and gloves;
536 medical devices, including IVD medical devices used in the private and public sector, donated from
537 donors, stains for microscopy and medical devices for veterinary use are not regulated. IVDs for
538 detecting and monitoring HIV, Malaria, TB, Syphilis and COVID-19 are somehow regulated but
539 ineffectively. IVDs are not effectively regulated because the conformity assessment ensures that the
540 products are safe and of acceptable quality, and performance is not standardised. Only performance
541 characteristics were verified. There was no technical documentation assessment, manufacturing site
542 inspections or labelling review to complement performance evaluation. Therefore, there is no assurance
543 that medical devices that are safe, of acceptable quality and perform as intended are marketed and used
544 for the Zimbabwean population.

545

546 To understand the context of how the MLCSscCZ ended up conducting some IVD regulations, it was
547 indicated that MLCSscCZ assumed the role of responding to the need for procurement requirements to
548 ensure that IVDs had to go through an evaluation for them to be eligible to participate in national
549 tendering processes for HIV IVDs. The MLCSscCZ was granted the authority by the health minister to
550 coordinate IVD registration for public national tendering processes to facilitate procurement. In
551 response to the HIV pandemic, the minister of health realised the challenges faced with HIV testing
552 due to non-regulated HIV test kits. The minister directed the MLCSscCZ to coordinate the evaluation
553 of HIV test kits for national tendering processes and the selection of test kits for use as part of the HIV
554 Testing algorithm. These developments culminated in the establishment of the NMRL at Harare
555 Hospital as it was deemed to have the expertise to conduct the evaluations to verify the performance of
556 priority IVDs. Respondent KI04 said, *“From the onset of HIV, the then minister of health realised the*
557 *challenges we would face when we have a pandemic. So, we then directed the medical laboratory*
558 *council to evaluate what kits were used. They used to call it an evaluation of test kits and devices for*
559 *HIV, and then it extended to malaria and TB. But the onset of it started during the time of HIV/AIDS*
560 *when the government needed to have one system of testing HIV and AIDS so that they use the same*
561 *parameters and guidelines to ascertain the impact of HIV and AIDS without using a multiplex of kits”*
562 (MLCSscCZ KII4).

563
564 On the other hand, the MCAZ started regulating gloves and condoms as IVDs in response to the HIV
565 pandemic despite not having the legal mandate. Respondent MCAZ KII1 highlighted this point by
566 saying, *“We test for gloves though there is low risk because of HIV. Condoms are tested because we*
567 *have been hit so badly”*.

568

569 The MLCScCZ appreciated that they did not have the mandate to regulate IVDs but "claimed" it was
570 MCAZ's mandate, but the MCAZ was not regulating the IVDs. Therefore, there was a vacuum., *"I think*
571 *things might improve because it's like so, whether we like it or not, MCAZ does have the regulatory*
572 *powers to do things we're talking about, and then we try to do it as far as soon as possible."* (MLCScCZ
573 *KII3*). A single coordinated approach that establishes roles and responsibilities makes formulating and
574 enforcing regulations more feasible. The acknowledgement of MLCScCZ that it does not have the legal
575 mandate to regulate IVDs shows some progress from when a similar study was conducted by
576 Dancombe et al. The study investigated the stakeholder perceptions on current and future regulation of
577 HIV Self-Testing IVDs in Malawi, Zambia and Zimbabwe. It was concluded that Zimbabwe did not
578 have clarity on its mandate to regulate the HIV Self Testing IVDs; MCAZ and MLCScCZ both claimed
579 the mandate. In the same study, one key informant from the MCAZ felt the need for HIV Self Test
580 IVDs to be regulated by only one regulator and that there must be some collaboration with the
581 MLCScCZ. There is an expectation that the MLCScCZ will work with MCAZ to regulate IVDs through
582 an advisory committee from the MLCScCZ that will advise on IVD regulatory functions. Respondent
583 MLCScCZ KI03 stated, *"But I think I'm happy to advise that we have now agreed that the council was*
584 *trying to collaborate with MCAZ. Terms of reference for council members to be part of the advisory*
585 *experts' committee within MCAZ are in their draft format."*
586 The realisation by the MLCScCZ of the need to collaborate with the MCAZ on IVD medical device
587 regulation is a step in the right direction to strengthen collaboration and coordination of IVD medical
588 device regulation. The representative from NMRL indicated that it needed to be clarified if NMRL had
589 the legal mandate to perform laboratory testing to support market authorisation of IVDs. Legal
590 provisions must be implemented to ensure that the NMRL can formally conduct laboratory testing for
591 IVDs.

592

593 Conformity assessment is conducted before and after a medical device is placed on the market. Post-
594 market surveillance of devices in actual use ensures that the medical device continues to meet the safety
595 and performance requirements and that the benefit-risk ratio maintains public confidence (5). The
596 conformity assessment must be proportional to the risk classification of the medical device. The MCAZ
597 assessed the dossiers to verify if the manufacturer's claims about the product were substantiated by
598 analytical and clinical evidence where applicable, manufacturing site inspection, and product
599 performance evaluation for gloves and condoms. *“ The assessment is conducted if the product meets
600 the requirements, the recommendation is made to the registration committee for decision-making for
601 granting market authorisation. The samples are tested, and if they meet the performance
602 characteristics, a provisional approval is granted, pending manufacturing site inspection”* (MCAZ
603 KII1). It is unclear why MCAZ prioritised the regulation of gloves considering that there are classified
604 as Class A and B(low risk) according to the classification rules for the GHTF guidance. Regulating
605 condoms is justifiable since they are Class C devices for contraception or the prevention of sexually
606 transmitted diseases (6). There is a need to adopt risk classification and conformity assessment
607 proportional to the product's risk class. This approach's advantage is reduced workload and regulatory
608 burden to the manufacturers. This, in turn, results in effective and efficient use of resources whilst
609 making access to the products more quickly to the population that needs them the most (5).

610
611 On the other hand, the MLScCZ bases its registration only on a limited performance evaluation
612 conducted at the NMRL. However, NMRL staff were not trained on the regulatory functions that
613 require independent performance evaluation of IVDs to support market authorisation decisions. The
614 NMRL did not have access to the Clinical and Laboratory Standards Institute (CLSI) that guides
615 laboratorians in developing and implementing protocols for validating and verifying IVDs. NMRL did
616 not have access to reference panels traceable to an International Standard. The reference panels are

617 standardised specimens for calibration and harmonisation of assays that detect specific pathogens, for
618 example, HIV antibodies or antigens and TB nucleic acids. Performance evaluation criteria were only
619 based on diagnostic sensitivity and specificity characteristics. Other aspects include analytical
620 sensitivity and specificity that challenge the product's Limit of Detection (LoD), investigation of cross-
621 reactivity, potentially interfering substances, precision and flex and robustness, and lot-to-lot variation
622 of the product were not being assessed by the NMRL. The implications are that the MLCSscZ registers
623 IVD medical devices and if not approved by any other stringent regulatory authorities, may not meet
624 the safety and performance requirements to ensure the safety of the patients. The regulatory system
625 must use reliance and recognition mechanisms to ensure that medical devices that may not have been
626 assessed stringently by the regulatory authority in Zimbabwe but approved by other stringent regulatory
627 authorities provide some assurance. However, the legislation in Zimbabwe does not allow reliance and
628 recognition mechanisms. Reliance must operate within existing legal frameworks. This means that
629 when an NRA relies on stringent assessments conducted by other jurisdictions, the relying NRA must
630 still make its own decisions on approving or not approving the products. The relying authority remains
631 independent, responsible and accountable regarding the decisions taken, even when it relies on the
632 findings, assessments and information of others. The reliance mechanism is meant to reduce the barriers
633 to access of IVDs due to unclear regulations and a lack of legal provisions to implement it. Regulatory
634 reliance enables healthcare systems to;

- 635 • accelerate global access to safe and quality health technology,
- 636 • increase efficient use of resources and avoid duplication of efforts,
- 637 • reduce uncertainties for innovators and improve harmonisation in regulation,
- 638 • promote more consistent and robust responses to crises (15).

639

640 The WHO prequalification programme informs procurement of quality-assured IVDs in RLS. It uses a
641 standardised procedure to assess if IVDs meet the specific safety, quality and performance
642 requirements. The assessment includes a technical documentation review, manufacturing site
643 inspection, performance evaluation and labelling review (16). It can also expedite the registration of
644 IVDs in other countries through improved information sharing between WHO prequalification, NRAs
645 and manufacturers through a reliance mechanism called the Collaborative Registration Procedure
646 (CRP). Leveraging assessment and inspection outputs already produced by WHO prequalification,
647 thereby eliminating duplicative regulatory work, speeds up in-country registration of quality-assured
648 products.

649 Additionally, the CRP conducts assessments with RLS in mind. It contributes to their wider availability
650 (17). This procedure can be one of the solutions for Zimbabwe to expedite IVD registration due to the
651 limited capacity to regulate these products. Effective implementation of this mechanism may require
652 the MASCA to be amended to include reliance mechanisms in the legislation.

653

654 Post-market surveillance (PMS) activities are not well documented. The MCAZ has not been doing
655 much for condoms and gloves. *"Currently, we have not been doing it. We have not been doing much
656 from our end. That has been our weakness. The only thing we have been doing is going around the
657 country to check for unregistered medical devices. Our regulations are not so explicit on post-market
658 surveillance, but that has been addressed in the draft regulations. Our strategy is that the
659 pharmacovigilance team may handle it (MCAZ KIII)."* This contradicts Hubner et al.'s finding that the
660 MCAZ had PMS in place (9). The MLCSCcZ acknowledged a process for pre-distribution lot-to-lot
661 testing conducted at NMRL and a mechanism to report and investigate user feedback if potential

662 failures of IVDs are suspected though not well documented. One respondent commented, "*So whenever*
663 *they're those adverse reports, the local distributor would immediately be informed and engaged with*
664 *respect by the ministry of health through the lab directorate at that time although the things were not*
665 *done correctly. But if the book followed them, those reports they have come out, and the technical*
666 *advisory committee would have advised the lab director. This is why the council was involved;*
667 *professionals regulated by the council are running these tests (MLCScCZ KII4."* Some contributing
668 factors to such weaknesses could be a lack of capacity to establish, implement and maintain
669 mechanisms for a robust PMS and a lack of effort in strengthening the regulatory system of medical
670 devices, including IVDs. Dube-Mwedzi et al. also found these when they conducted a rapid assessment
671 of national regulatory systems in SADC. This is consistent with the finding in the study conducted by
672 Stanislav et al. that most of the countries in the SADC region did not have a policy framework to
673 underpin the prevention, detection and response to incidences of substandard, falsified medical
674 products, handling of market complaints, control of promotion of medical devices, detection of and
675 action against substandard and falsified medical devices, removal and disposal of defective medical
676 devices (18).

677 The interviewed participants recognised the need for collaboration and improving medical device
678 regulation. "*Well, the need for regulation must be balanced, but we cannot do all the regulatory*
679 *functions. There is a need to have the training and technical support, including infrastructure and*
680 *equipment to conduct the regulatory functions, human resources that are trained and competent to*
681 *conduct the work, and mechanisms to ensure transparency and accountability."* (NMRL KII8).
682 Another participant said, "*I think lack of consensus resulted in working in silos and on professional*
683 *differences. Laboratory scientists look at IVDs as tools of their trade that must be regulated by*
684 *scientists. This made it challenging for MCAZ and the MLCScCZ to work together, leading to a*

685 *deadlock. Both institutions are on talking terms now, and we hope to see progress” (MLCScCZ KII12).*

686 Therefore, when coming up with the road map, it is essential for the regulatory authority to consider

687 different and applicable professionals to ensure that staff with the right qualifications, competencies

688 and skills conduct the regulatory work. This requires a multi-sectoral approach using system thinking.

689 The approach needs to consider the following key stakeholders;

690 1. Practitioners and researchers

691 2. Advocates

692 3. Industry representatives

693 4. Leaders.

694 Effective medical device regulation requires system organising, systems dynamics, systems networks

695 and systems knowledge. The following are the definitions of the terms listed above;

696 • *“Systems organise to understand and foster the development of participatory, complex, and*
697 *adaptive collaborative systems regulating medical devices; ensure effective facilitation and*
698 *management; and encourage productive system action and learning.*

699 • *System dynamics to understand and model the complex dynamic interactions involved in the*
700 *regulatory system and among the factors influencing medical device use, including political*
701 *actions such as legislation, research advances, medical device control activities, industry*
702 *forces, and social and cultural factors.*

703 • *System networks to understand and analyse effective collaborative relationships among*
704 *stakeholders, improve collaboration strategies, and help reduce duplication of effort.*

705 • *Systems knowledge to develop and manage the knowledge infrastructure required for effective*
706 *dissemination and evolution of scientifically credible, evidence-based practices, together with*
707 *an effective strategy to package, deliver, and maintain this knowledge” (figure 1) (19).*

708 Concluding the findings from interviewing participants from Zimbabwe, it appears that
709 Zimbabwe is on the pathway to strengthening medical device regulations. This requires
710 collaboration and systems thinking to ensure the medical devices regulatory system is effective.
711

712 The GMRFMD is essential to guide NRAs to establish and strengthen the medical devices
713 regulatory system. The findings have shown that the framework is popular among regulatory
714 authorities in developing countries. Revision of the GMRFMD to include GBT + medical
715 devices indicators into the GMRFMD. This revision intends to consider factors for advanced
716 regulation of medical devices: "Understanding that this model was developed, uh, in 2016, the
717 drafting was in 2016, publishing was in 2017, and years have passed since *this document was*
718 *drafted and published. And so the discussion in the GBT, uh, indicators triggered revision.*"
719 (WHO KII13). South Africa modelled its medical devices regulatory systems from the
720 GMRFMD and the WHO Global Benchmarking Tool. "*So the roadmap indicated that they're*
721 *following the WHO Global Benchmarking (GBT) process for implementing the medical device*
722 *regulations in the country (SAHPRA KII14)". SAHPRA and TMDA had to develop an action*
723 *plan to improve the regulatory system of medical devices. In the case of South Africa, it had to*
724 *benchmark the medical devices regulatory system using the GBT to determine the baseline*
725 *status.*

726 Additionally, the regulator compared its regulatory approaches with other agencies, namely
727 Australia's Therapeutic Goods Administration (TGA), Canada's Health Canada, Singapore's
728 Health Science Authority (HSA) and Switzerland's Swissmedic. The purpose of the
729 comparison was to identify areas of improvement and harmonise the regulatory system. The
730 study also informed the re-engineering of the NRA, resulting in its name change from the
731 Medicines Control Council (MCC) to the South African Health Products Regulatory Authority
732 (SAHPRA). It was concluded that MCC used similar Good Regulatory Review Practices
733 (GRevP) compared to Australian, Canadian, Singapore, and Swiss NRAs. However, review

734 timelines to grant product market authorisation were more extended than other NRAs (20,21).

735 Similarly, Tanzanian NRA built its case by comparing the then position and best practices from

736 USFDA, TGA and PMDA: *“So we made sure that we had a, a lot of references, we had a lot*

737 *of information from other mature jurisdictions such as, such as the USFDA, TGA, Japan, all*

738 *these other big, uh, national regulatory authorities to say what is happening in other countries*

739 *that have made, uh, uh, tremendous, uh, progress in this, in this space for harmonisation*

740 *purposes.”* (WHO KII15). Another study also included Health Canada to benchmark the

741 medical devices regulatory authority (12). The advantage of this approach is that it also was to

742 harmonise the regulations to implement reliance and recognition mechanisms. Stakeholder

743 engagement and advocacy are essential to capture all the stakeholders' views. Stakeholders

744 must include policymakers, regulators, and economic operators to ensure acceptance of the

745 regulations.

746 There is a need to promote convergence and harmonisation of medical device regulations.

747 Convergence is a process *“whereby the regulatory requirements across countries or regions*

748 *become more similar or “aligned” over time as a result of the gradual adoption of*

749 *internationally recognised technical guidance documents, standards and scientific principles,*

750 *common or similar practices and procedures, or adoption of regulatory mechanisms that might*

751 *be specific to a local legal context but that align with shared principles to achieve a common*

752 *public health goal.”* Harmonisation is a process by which technical guidelines are developed

753 *to be uniform across participating authorities.* (22). Learning from the South African and

754 Tanzanian experiences, convergence, and harmonisation are vital in reducing the regulatory

755 burden on manufacturers and regulators. Furthermore, in the study conducted by Keyter et al.,

756 it was recommended to implement facilitated regulatory pathways and apply a risk-based

757 approach to the regulatory review process to conserve limited resources, avoid duplication of

758 regulatory efforts and get the medical devices to the populations that need them the most (20).

759

760 The experiences from South Africa and Tanzania are essential to Zimbabwe amending the
761 MASCA to address the following;

- 762 • *"Explicitly state the institution (s) with the legal mandate to regulate medical devices*
763 *with powers to enforce the regulations and market oversight.*
- 764 • *Define medical devices and the scope of medical devices regulated under this law,*
765 *ensuring the regulatory framework is capable of adapting to new technologies and*
766 *treatment modalities.*
- 767 • *Stakeholder responsibilities, powers to issue implementing regulations and to take*
768 *action where the health of patients or users is compromised, and the responsibility for*
769 *publishing guidance documents to aid understanding of legal requirements;*
- 770 • *provide the regulatory authority with administrative and enforcement discretion for*
771 *reliance upon and recognition of the work or decisions of regulatory authorities in*
772 *other jurisdictions;*
- 773 • *require that only safe medical devices that perform as the manufacturer describes in its*
774 *labelling may be placed on the market;*
- 775 • *specify market entry conditions for medical devices;*
- 776 • *establish record-keeping, registration and reporting requirements for all parties within*
777 *the scope of the law, including the regulatory authority;*
- 778 • *specify a transition period sufficient to allow parties affected by the law to comply with*
779 *its requirements and ensure minimal disruption to the continuing supply of medical*
780 *devices to health facilities and other users" (13).*

781

782 The challenges encountered in the transition of the regulations were the capacity and
783 competencies to regulate medical devices, including IVDs. Most personnel within TMDA were

784 pharmacists and were unfamiliar with frameworks for medical devices, including IVDs. There
785 was the need for a complete mindset shift during the transition period: to switch from
786 pharmaceuticals to medical devices and regulation. The interviewee commented, "*I say that,*
787 *of course, you must learn. So when it comes to learning, you need people willing to learn and*
788 *consider that. And of course, medical devices are diverse, so it depends on multi-disciplinary*
789 *teams for the issues and how to accommodate the groups*" (TMDA KI15). In the context of
790 SAHPRA, the interviewee said, "*The structure comprised chiefly of the pharmacists needed*
791 *some changes to accommodate other professionals, such as medical engineers and scientists,*
792 *to advice on regulatory affairs of medical devices (SAHPRA KI14).*" The TMDA now has a
793 multi-disciplinary team of external experts associated with the design, development,
794 manufacturing, evaluation and use of medical devices that was put in place to advise the TMDA
795 with basic understanding and conformity assessment-related work, including all other
796 regulatory functions of the NRA. The medical devices department has now grown to an entire
797 directorate within the TMDA, with about 40 staff members employed by the TMDA. The other
798 challenge the TMDA faced was the temptation to use the medicines regulatory framework on
799 medical devices, including IVDs. It is appreciated that the medicines regulatory framework has
800 matured over the years and is stable, but it does not apply to medical devices. The interviewee
801 commented, "*For example, in the context of medicines, it is apparent that from production,*
802 *products with a shelf life of 36 months should have at least 80% of the shelf life remaining.*
803 *Medicines with a shelf life of 24 months should have at least 60% remaining by the time they*
804 *arrive at the port of entry (TMDA KII15).*" This approach does not apply to reagents and
805 controls that fall under IVDs with a shorter shelf life of fewer than six weeks; by the time they
806 arrive at the port of entry, they might be left with two weeks. The interviewee commented, "*So*
807 *in terms of when you start regulations, it's imperative to disengage regulations from those*
808 *medical devices, from the ones for medicine, as early as possible, to make people open-minded,*

809 *and to treat medical devices the way they are supposed to be treated following their life cycle*

810 (TMDA KII15)." Therefore, it is recommended that the NRA develop a framework specific for

811 medical devices following medical devices' lifecycle depending on the nature of design and

812 intended use of the medical device.

813

814 The main output of this study is a roadmap for Zimbabwe to establish, implement and

815 continuously improve a responsive, predictable, standardised and transparent regulatory

816 system oriented to the outcome. The proposed roadmap uses a tired approach. The three tiers

817 are legislation, regulations and guidance. Legislation subjected to public scrutiny and does

818 not contradict the Constitution is the mainstay of regulations. Regulations interpret the law

819 and make the implementation of the law feasible. The guidance provides manufacturers with

820 instructions to meet the requirements of the regulations (2).

821

822 Furthermore, a competence framework is proposed because human resources are important

823 for an effective medical regulatory system. The competence framework is adopted from the

824 Regulatory Affairs Professionals Society competence framework and is cross-cutting on

825 legislation, regulations and guidance (23). The proposed road map is shown in Figure 2

826 below.

827

828 **Study Limitations**

829 There are limitations to this research, as well as issues related to implementing a case study.

830 One of the limitations is that the study did not include the Ministry of Health officials, users of

831 the medical devices, the donor community, procurers, manufacturers, importers, authorised

832 representatives and distributors of medical devices to get their perception of the current state

833 of medical devices regulation in Zimbabwe. The results of this study cannot be generalised to

834 the broader research community due to the nature of the research strategy. The researcher uses
835 a tried and tested research strategy, appealing to relatability rather than generalizability.
836 However, it was also argued that generalisation, although not immediate, can take place over
837 some time – incremental generalizability – as more empirical research case studies are
838 implemented. Data saturation was not achieved regarding sample size as the number of
839 interviewees from Zimbabwe did not reach 15.

840

841 **Conclusions**

842 Medical devices in Zimbabwe are not adequately regulated. The role of effective medical
843 device regulation is recognised to ensure that safe medical devices of acceptable quality and
844 performance are made accessible to the populations that need them the most without delay due
845 to unclear regulatory processes. The legal framework needs to be amended to ensure that
846 medical device regulation is founded on a sound basis in law. It clearly states the institution(s)
847 with the legal mandate to regulate and enforce the regulations, define the products within its
848 scope, and identify the entities subject to regulation. The formulation, implementation and
849 enforcement of medical device regulations require systems thinking and multi-sectoral
850 collaboration. Harmonisation and reliance practices will make the regulatory system
851 predictable and proportional to the risk classification of medical devices and reduce the
852 regulatory burden on economic operators and the workload on the regulatory authority. Hence,
853 it will make medical devices expeditiously accessible.

854

855

856

857 Acknowledgements

858 The authors would like to acknowledge the cooperation of the agencies and personnel
859 interviewed in Zimbabwe, South Africa, Tanzania, and the WHO and for their assistance with
860 accessing documentary evidence and reports.

861

862 References

- 863 1. European Commission. MDR - Regulation (EU) 2017/746 on in-vitro diagnostic
864 medical devices. Off J Eur Union [Internet]. 2017;60(April 2014):1–175. Available
865 from: 1. European Commission. MDR - Regulation (EU) 2017/746 on in-vitro
866 diagnostic medical devices. Off J Eur Union [Internet]. 2017;60(April 2014):1–175.
867 Available from: [https://www.emergogroup.com/sites/default/files/europe-medical-](https://www.emergogroup.com/sites/default/files/europe-medical-devices-regulation.pdf%0Ah)
868 [devices-regulation.pdf%0Ah](https://www.emergogroup.com/sites/default/files/europe-medical-devices-regulation.pdf%0Ah)
- 869 2. REGULATORY AFFAIRS PROFESSIONALS SOCIETY.
870 *Fundamentals_of_Medical_Device_Regulations__Fifth_.pdf*. Fifth. Hall GN, editor.
871 Rockville: RAPS BOOKS; 2022. 748 p.
- 872 3. Global Harmonization Task Force (GHTF). Information Document Concerning the
873 Definition of the Term “Medical Device.” 2005;6. Available from:
874 [http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n29r16-2005-](http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n29r16-2005-definition-medical-device-050520.pdf)
875 [definition-medical-device-050520.pdf](http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n29r16-2005-definition-medical-device-050520.pdf)
- 876 4. GHTF. Global Harmonization Task Force Study Group 1: Definition of the Terms
877 ‘Medical Device’ and ‘In Vitro Diagnostic (IVD) Medical Device.’ Force, Study Gr 1
878 Glob Harmon Task [Internet]. 2012;(Ivd):6. Available from:
879 [http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n071-2012-](http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n071-2012-definition-of-terms-120516.pdf#search=%22ghtf%20definition%20Medical%20Device%202012%22)
880 [definition-of-terms-120516.pdf#search=%22ghtf definition ?Medical Device?](http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n071-2012-definition-of-terms-120516.pdf#search=%22ghtf%20definition%20Medical%20Device%202012%22)
881 [2012%22](http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n071-2012-definition-of-terms-120516.pdf#search=%22ghtf definition ?Medical Device?2012%22)
- 882 5. GHTF. Principles of Conformity Assessment for Medical Devices [Internet].
883 *Ghtf/Sg1/N78:2012*. 2012. Available from:
884 [https://www.imdrf.org/sites/default/files/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-](https://www.imdrf.org/sites/default/files/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n78-2012-conformity-assessment-medical-devices-121102.pdf)
885 [n78-2012-conformity-assessment-medical-devices-121102.pdf](https://www.imdrf.org/sites/default/files/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n78-2012-conformity-assessment-medical-devices-121102.pdf)
- 886 6. De Maria C, Di Pietro L, Díaz Lantada A, Madete J, Makobore PN, Mridha M, et al.
887 Safe innovation: On medical device legislation in Europe and Africa. *Heal Policy*
888 *Technol* [Internet]. 2018;7(2):156–65. Available from:
889 <https://doi.org/10.1016/j.hlpt.2018.01.012>
- 890 7. IMDRF. Essential Principles of Safety and Performance of Medical Devices. *Int Med*
891 *Device Regul Forum* [Internet]. 2018; Available from:
892 [https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-181031-](https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-181031-grp-essential-principles-n47.pdf)
893 [grp-essential-principles-n47.pdf](https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-181031-grp-essential-principles-n47.pdf)
- 894 8. World Health Organization. Health products policy and standards : Good
895 *Manufacturing Practices* [Internet]. 2018 [cited 2023 May 21]. Available from:

- 896 [https://www.who.int/teams/health-product-policy-and-standards/assistive-and-medical-](https://www.who.int/teams/health-product-policy-and-standards/assistive-and-medical-technology/medical-devices/regulations)
897 [technology/medical-devices/regulations](https://www.who.int/teams/health-product-policy-and-standards/assistive-and-medical-technology/medical-devices/regulations)
- 898 9. Hubner S, Maloney C, Phillips SD, Doshi P, Mugaga J, Ssekitoleso RT, et al. The
899 evolving landscape of medical device regulation in East, Central, and Southern Africa.
900 *Glob Heal Sci Pract* [Internet]. 2021 Apr 1 [cited 2021 Nov 10];9(1):136–48.
901 Available from: <https://pubmed.ncbi.nlm.nih.gov/33764886/>
- 902 10. Kniazkov S, Dube-Mwedzi S, Nikiema JB. Prevention, Detection and Response to
903 incidences of substandard and falsified medical products in the Member States of the
904 Southern African Development Community [Internet]. Vol. 13, *Journal of*
905 *Pharmaceutical Policy and Practice*. John Wiley & Sons, Ltd; 2020 [cited 2021 Sep
906 19]. p. e25229. Available from:
907 <https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25229>
- 908 11. Houston MJ, Sudman S. A methodological assessment of the use of key informants.
909 *Soc Sci Res*. 1975 Jun 1;4(2):151–64.
- 910 12. Rugera SP, McNERNEY R, Poon AK, Akimana G, Mariki RF, Kajumbula H, et al.
911 Regulation of medical diagnostics and medical devices in the East African community
912 partner states. *BMC Health Serv Res* [Internet]. 2014 Oct 31 [cited 2021 Sep
913 18];14(1):1–7. Available from:
914 <https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-014-0524-2>
- 915 13. World Health Organization (WHO). WHO Global Model Regulatory Framework for
916 Medical Devices including in vitro diagnostic medical devices. [Internet]. WHO
917 Medical device technical series. Licence: CC BY-NC-SA 3.0 IGO. 2017. 1–65 p.
918 Available from:
919 [http://apps.who.int/bookorders.%0Ahttp://apps.who.int/bookorders.%0Ahttps://www.
920 who.int/medical_devices/publications/global_model_regulatory_framework_meddev/
921 n/%0Ahttp://www.who.int/medicines/areas/quality_safety/quality_assurance/2016-07-
922 27Modelregulato](http://apps.who.int/bookorders.%0Ahttp://apps.who.int/bookorders.%0Ahttps://www.who.int/medical_devices/publications/global_model_regulatory_framework_meddev/n/%0Ahttp://www.who.int/medicines/areas/quality_safety/quality_assurance/2016-07-27Modelregulato)
- 923 14. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research
924 (COREQ): A 32-item checklist for interviews and focus groups. *Int J Qual Heal Care*
925 [Internet]. 2007 Dec 1 [cited 2023 Feb 15];19(6):349–57. Available from:
926 <https://academic.oup.com/intqhc/article/19/6/349/1791966>
- 927 15. Saint-Raymond A, Valentin M, Nakashima N, Orphanos N, Santos G, Balkamos G, et
928 al. Reliance is key to effective access and oversight of medical products in case of
929 public health emergencies. <https://doi.org/10.1080/1751243320222088503> [Internet].
930 2022 Aug 9 [cited 2022 Aug 15];1–6. Available from:
931 <https://www.tandfonline.com/doi/abs/10.1080/17512433.2022.2088503>
- 932 16. World Health Organization. Overview of the Who Prequalification of in Vitro
933 Diagnostics Assessment Who Prequalification of in Vitro Diagnostics [Internet]. 2017.
934 Available from: www.who.int
- 935 17. World Health Organisation. Collaborative registration procedure (CRP) for in vitro
936 diagnostics (IVDs) – Information note Collaborative registration procedure (CRP)
937 for in vitro diagnostics (IVDs) – Information note [Internet]. 2019. Available from:
938 [https://cdn.who.int/media/docs/default-source/in-vitro-diagnostics/191111-crp-ivd-
939 information-note.pdf?sfvrsn=d2a8b5c_2&download=true](https://cdn.who.int/media/docs/default-source/in-vitro-diagnostics/191111-crp-ivd-information-note.pdf?sfvrsn=d2a8b5c_2&download=true)

- 940 18. Kniazkov S, Dube-Mwedzi S, Nikiema JB. Prevention, Detection and Response to
941 incidences of substandard and falsified medical products in the Member States of the
942 Southern African Development Community [Internet]. Vol. 13, Journal of
943 Pharmaceutical Policy and Practice. J Pharm Policy Pract; 2020 [cited 2022 Jul 29].
944 Available from: <https://pubmed.ncbi.nlm.nih.gov/33088577/>
- 945 19. National Cancer Institute. Monograph 18: Overview. In: Greater Than the Sum:
946 Systems Thinking in Tobacco Control Tobacco Control Monograph No 18 [Internet].
947 Bethesda MD: Department of Health and Human Services, National Institutes of
948 Health, National Cancer Institute. NIH Pub; 2007 [cited 2021 Aug 28]. p. 1–9.
949 Available from: <https://cancercontrol.cancer.gov/brp/tcrb/monographs/monograph-18>
- 950 20. Keyter A, Salek S, Banoo S, Walker S. The South African Medicines Control Council:
951 Comparison of Its Registration Process With Australia, Canada, Singapore, and
952 Switzerland. Front Pharmacol. 2019;10(March):1–11.
- 953 21. Keyter A, Gouws J, Salek S, Walker S. The Regulatory Review Process in South
954 Africa: Challenges and Opportunities for a New Improved System. Ther Innov Regul
955 Sci. 2018;52(4):449–58.
- 956 22. Food US, Cooperation AE, Sciences L, Forum I, Harmonization R, Committee S.
957 Regulatory Harmonization and Convergence. US Food Drug Adm [Internet]. 2016
958 [cited 2023 Mar 12];1–4. Available from: <https://www.fda.gov/vaccines-blood-biologics/international-activities/regulatory-harmonization-and-convergence>
- 960 23. RAPS. Regulatory Competency Framework. 2021 [cited 2022 Jul 28]; Available from:
961 <https://www.raps.org/resources/regulatory-competency-framework>
- 962




Figure 1: Proposed stakeholder engagement and systems thinking approach for medical devices regulation in Zimbabwe




Figure 2: A road map to address deficiencies identified in medical devices regulation in Zimbabwe